Gapping down
In reaction to disappointing earnings/guidance:
- HIBB -10.4%, (sees Q4 results below estimates, offers light FY18 guidance), AMKR -10.4%, RCII -6.4%, TTM -5.9%, VG -5.2%, NTWK -5.1%, RNG -4.6%
- BKD -4.6%, TTS -3%, FLO -1.9%, DBD -1.8%, ACOR -1.6%, AGII -1.4%, TMUS -1.3%, INCY -1%, BRX -0.9%, CUTR -0.5%
M&A news:
- PLKI -3.3% (Restaurant Brands (QSR) might have walked away from potential M&A deal with PLKI, according to NY Post), HOLX -2% (to acquire CYNO for $66 per share)
Other news:
- AVIR -37% (announces top-line data from its Phase 2b SPIRITUS trial of Vapendavir; Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo)
- GEVO -25.3% ( announces proposed public offering of common stock and warrants; announces that WB Gevo, Ltd., the holder of the Co's issued and outstanding 10% Convertible Senior Notes, due 2017, and the Co have agreed to extend the maturity date of the 2017 Notes from March 15, 2017 to June 23, 2017 )
- ATOS -9.8% (files for $4 mln common stock offering )
- BGFV -5.1% (following HIBB guidance)
- GLNG -4.9% (to offer $350 million aggregate principal amount of Convertible Senior Notes )
- PFLT -3.7% (plans to make a public offering of 5,000,000 shares of its common stock )
- DNR -2.6% (reports year-end 2016 proved reserves and preliminary 2016 production)
- FXCM -1.7% (issues statement on the settlement of the civil action filed by the Commodity FTC regarding the brief undercapitalization FXCM US suffered as the direct result of the Swiss National Bank; includes a fine of $650)
- DKS -0.8% (following Hibbett Sporting guidance)
Analyst comments:
- DEPO -1.5% (downgraded to Neutral at Mizuho)
- USAC -1.4% (downgraded to Sector Perform at RBC)
- NSP -1.2% (downgraded to Neutral at Roth)
- JCI -0.5% (downgraded to Hold from Buy at Argus)